期刊文献+

Pluronic载体在抗肿瘤聚合物胶束的研究进展 被引量:1

Advances of Anti-tumor Polymeric Micelles by Pluronic Carrier
下载PDF
导出
摘要 多药耐药性是近年来癌症化疗失败的主要原因,药物传递系统为逆转肿瘤细胞的多药耐药性提供了一条有效途径。以Pluronic为载体的聚合物胶束由于其自身具有可以逆转MDR的特性,作为一种新型抗肿瘤药物传递系统备受关注。本文主要对Pluronic的生物特性、逆转MDR的机制及药物载体功能进行综述。 Drug delivery system provides an effective way to reverse multidrug resistance (MDR) which is one of the main reasons of cancer chemotherapy failure in recent years. Among lhem, lhe polymeric mieelles of pluronie as a new anti-tumor drug delivery system al- tract much attention because of their unique properties of reversing MDR. In this paper reviewed were the biological characteristics, the mechanism of reversing MDR, and the function of drug carrier of Pluronie.
作者 李倩 尹东锋 LI Qian;YIN DongFeng*(Department of pharntacy,General Hospital of Xinjiang Military Command,Urumqi,Xinjia,zg,830000,China)
出处 《肿瘤药学》 CAS 2018年第4期487-493,504,共8页 Anti-Tumor Pharmacy
基金 国家自然科学基金(81372782)
关键词 普朗尼克 聚合物胶束 药物载体 多药耐药性 Pluronie Polymeric mieelles Drug eaMer Multidrug resistance
  • 相关文献

参考文献8

二级参考文献52

  • 1胡一桥,郑梁元,钱陈钦,郁伟海.离子型药物酚红的小肠吸收研究[J].中国药科大学学报,1996,27(6):355-359. 被引量:56
  • 2Li-mei HAN Jie GUO Li-jun ZHANG Qing-song WANG Xiao-ling FANG.Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123[J].Acta Pharmacologica Sinica,2006,27(6):747-753. 被引量:7
  • 3韩旻,韩丽妹,王青松,白志华,方晓玲.三七皂苷的口服吸收机制[J].药学学报,2006,41(6):498-505. 被引量:45
  • 4田莉,杨秀伟,王莹,徐嵬.顺式-和反式-阿霍烯在Caco-2细胞模型中的体外摄取、转运和外排特性[J].药学学报,2007,42(1):87-92. 被引量:7
  • 5Camenisch G,Folkers G,Waterbeemd H.Comparison of passive drug transport through Caco-2 cells and artificial membranes[J].Int J Pharm,1997,147:61-70.
  • 6Tetao T,Hisanaga E,Sai Y,et al.Active secretion of drugs from the small intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier[J].J Pharm Pharmacol,1996,48:1083-1089.
  • 7Cornair G,Woodley J,Hermann P,et al.Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo[J].Int J Pharm,2004,278:119-131.
  • 8Yee S.In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth[J].Pharm Res,1997,14:763-766.
  • 9Varma MV,Ashokraj Y,Dey CS,et al.P-glycoprotein inhibitors and their screening:a perspective from bioavailability enhancement[J].Pharm Res,2003,48:347-359.
  • 10Walle UK,Walle T.Taxol transport by human intestinal epithelial Caco-2 cells[J].Drug Metab Dispos,1998,26:343-346.

共引文献28

同被引文献12

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部